| Literature DB >> 35136128 |
Azam Doustmohammadian1, Cain C T Clark2, Mansooreh Maadi1, Nima Motamed3, Elham Sobhrakhshankhah1, Hossein Ajdarkosh1, Mohsen Reza Mansourian1, Saeed Esfandyari4, Nazanin Asghari Hanjani5, Mahsa Nikkhoo1, Farhad Zamani6.
Abstract
Nonalcoholic fatty liver disease (NAFLD) is an emerging cause of chronic liver diseases and a major health problem worldwide. Dietary patterns may play a critical role in controlling and preventing this disease, but the available evidence is scarce. The current study aims to ascertain the association of adherence to the Dietary Approach to Stop Hypertension (DASH) diet and Mediterranean diet (MeD) with nonalcoholic fatty liver disease (NAFLD) among Iranian adults of the Amol Cohort Study (AmolCS). In a cross-sectional analysis among 3220 adults (55.3% men), age ≥ 18 years (46.96 ± 14.67), we measured usual dietary intake with a validated food frequency questionnaire (FFQ) and then calculated dietary pattern scores for DASH and MeD. Sociodemographic and lifestyle factors were collected by a structured questionnaire. The presence and degree of NAFLD were also determined by abdominal sonography. Multiple regression models were used to estimate NAFLD odds across tertiles of DASH and Mediterranean dietary scores. Dietary DASH and Mediterranean components were adjusted for total energy intake, based on the residual methods. After adjusting for multiple potential confounders, we found an inverse association of DASH and MeD with NAFLD (Ptrend = 0.02, and Ptrend = 0.002, respectively). Those in the highest tertiles of adherence to the DASH and MeD had the lowest risk for NAFLD (OR = 0.80, 95%CI = 0.66-0.96, OR = 0.64, 95%CI = 0.52-0.78, respectively). The results of logistic analysis of MeD, stratified by gender and abdominal obesity, revealed the favorable association was more pronounced in women (OR = 0.42, 95%CI = 0.29-0.61, Ptrend = 0.004), and in participants with or without abdominal obesity (OR = 0.62, 95% CI = 0.47-0.81, Ptrend = 0.03, OR = 0.64, 95%CI = 0.475-0.91, Ptrend = 0.04, respectively). Similar results were obtained for the adherence to DASH diet score with the prevalence of NAFLD patients with abdominal obesity (OR = 0.75, 95% CI = 0.57-0.97, Ptrend = 0.04). The findings suggested the favorable association between DASH and MeD with NAFLD in Iranian adults, especially women and subjects with or without abdominal obesity. Further prospective investigations are needed to confirm the integrity of our findings.Entities:
Mesh:
Year: 2022 PMID: 35136128 PMCID: PMC8825797 DOI: 10.1038/s41598-022-06035-8
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Baseline characteristics of the study adult participants (n = 3220, aged ≥ 18 years), Amol Cohort Study, Iran, 2016–2017.
| Characteristic | Women | Men | P value | Non-NAFLD | NAFLD | P value | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| N/mean | %/SD | N/mean | %/SD | N/mean | %/SD | N/mean | %/SD | |||
| n and % | 1438 | 44.7 | 1782 | 55.3 | – | 1783 | 55.4 | 1437 | 44.6 | – |
| Age (years) | 45.68 | 14.05 | 48.00 | 15.08 | < 0.001 | 45.59 | 16.11 | 48.65 | 12.47 | < 0.001 |
| BMI (kg/m2) | 29.52 | 5.33 | 26.78 | 4.34 | < 0.001 | 25.96 | 4.38 | 30.54 | 4.53 | < 0.001 |
| Waist circumference (cm) | 87.90 | 12.05 | 89.63 | 10.48 | < 0.001 | 83.91 | 9.95 | 94.95 | 9.64 | < 0.001 |
| Smoker | 8 | 0.6 | 459 | 25.8 | < 0.001 | 285 | 16.00 | 182 | 12.70 | 0.008 |
| Alcohol drinker | 5 | 0.40 | 233 | 10.70 | < 0.001 | 97 | 5.60 | 92 | 6.60 | 0.24 |
| Diabetes | 278 | 19.30 | 196 | 11.00 | < 0.001 | 174 | 9.80 | 300 | 20.09 | < 0.001 |
| Metabolic syndrome | 512 | 35.60 | 354 | 19.90 | < 0.001 | 238 | 13.40 | 628 | 43.70 | < 0.001 |
| Heart disease | 50 | 3.50 | 94 | 5.30 | 0.01 | 81 | 4.50 | 63 | 4.40 | 0.82 |
| Lowering serum glucose agent’s user (%) | 90 | 6.3 | 94 | 5.3 | 0.23 | 73 | 4.1 | 111 | 7.9 | < 0.001 |
| Lowering serum lipid agent’s user (%) | 204 | 14.2 | 175 | 9.8 | < 0.001 | 181 | 10.2 | 198 | 13.8 | 0.001 |
| Lowering hypertension agent’s user (%) | 303 | 21.1 | 290 | 16.3 | < 0.001 | 288 | 16.2 | 305 | 21.2 | < 0.001 |
| Rural | 520 | 36.20 | 905 | 50.08 | < 0.001 | 788 | 44.20 | 637 | 44.30 | 0.94 |
| Urban | 918 | 63.80 | 877 | 49.20 | 995 | 55.80 | 800 | 55.70 | ||
| Very low | 486 | 34.20 | 506 | 28.70 | < 0.001 | 514 | 29.30 | 478 | 33.50 | 0.06 |
| Low | 582 | 41.0 | 676 | 38.30 | 703 | 40.0 | 555 | 38.90 | ||
| Moderate | 72 | 5.10 | 101 | 5.70 | 102 | 5.80 | 71 | 5.0 | ||
| high | 280 | 19.70 | 482 | 27.30 | 438 | 24.90 | 324 | 22.70 | ||
| TG (mg/dl) | 127.93 | 88.34 | 138.15 | 91.23 | 0.001 | 111.79 | 65.41 | 160.63 | 107.50 | < 0.001 |
| Total cholesterol (mg/dl) | 183.47 | 41.94 | 178.31 | 38.85 | < 0.001 | 176.12 | 39.16 | 186.19 | 41.08 | < 0.001 |
| HDL(mg/dl) | 46.10 | 11.76 | 41.77 | 11.36 | < 0.001 | 44.70 | 11.81 | 42.48 | 11.52 | < 0.001 |
| LDL(mg/dl) | 99.69 | 26.72 | 98.72 | 26.16 | 0.30 | 97.45 | 26.65 | 101.26 | 25.97 | < 0.001 |
| SBP (mmHg) | 113.51 | 20.48 | 115.79 | 18.04 | 0.001 | 111.24 | 18.30 | 119.15 | 19.40 | < 0.001 |
| DBP (mmHg) | 70.78 | 12.28 | 72.36 | 11.36 | < 0.001 | 69.14 | 11.11 | 74.78 | 11.89 | < 0.001 |
| FBS (mg/dl) | 108.45 | 40.33 | 103.68 | 29.79 | < 0.001 | 100.85 | 30.77 | 111.97 | 38.70 | < 0.001 |
| HbA1C | 4.60 | 0.94 | 4.53 | 0.90 | 0.02 | 4.46 | 0.86 | 4.69 | 0.96 | < 0.001 |
| ALT (mg/dl) | 19.74 | 13.89 | 27.50 | 20.23 | < 0.001 | 20.19 | 14.60 | 28.81 | 20.70 | < 0.001 |
| AST (mg/dl) | 19.44 | 8.22 | 23.35 | 11.56 | < 0.001 | 20.73 | 10.89 | 22.69 | 9.62 | < 0.001 |
| GGT (mg/dl) | 24.04 | 18.54 | 29.42 | 19.07 | < 0.001 | 23.86 | 17.79 | 30.94 | 19.76 | < 0.001 |
| ALKP (mg/dl) | 195.87 | 67.37 | 199.34 | 53.05 | 0.10 | 193.08 | 61.76 | 203.65 | 56.96 | < 0.001 |
NAFLD: nonalcoholic fatty liver disease; PA: physical activity, MET: metabolic equivalent of task, BMI: body mass index, ALT: alanine transaminase, AST: aspartate transaminase, GGT: gamma-glutamyl transferase, ALKP: alkaline phosphatase.
Significant at P < 0.05 for independent t-test for continuous variables and chi-square test for dichotomous variables.
Dietary patterns of the study adult participants (n 3220, aged ≥ 18 years), Amol Cohort Study, Iran, 2016–2017.
| Characteristic | Women | Men | P value | Non-NAFLD | NAFLD | P value | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| N/mean | %/SD | N/mean | %/SD | N/mean | %/SD | N/mean | %/SD | |||
| Energy (kcal/d) | 2171.07 | 599.92 | 2458.24 | 685.51 | < 0.001 | 2326.48 | 668.73 | 2334.35 | 658.55 | 0.73 |
| Vegetables (serving/d) | 2.73 | 1.67 | 2.60 | 1.88 | 0.04 | 2.61 | 1.78 | 2.72 | 1.79 | 0.08 |
| Fruits (serving/d) | 2.82 | 3.56 | 3.01 | 4.42 | 0.20 | 2.99 | 4.17 | 2.85 | 3.91 | 0.34 |
| Nuts and legumes (serving /d) | 1.75 | 1.21 | 1.69 | 1.33 | 0.18 | 1.71 | 1.30 | 1.72 | 1.25 | 0.93 |
| Low Dairy products (serving/d) | 0.56 | 0.43 | 0.53 | 0.47 | 0.04 | 0.54 | 0.47 | 0.54 | 0.44 | 0.97 |
| Whole grains and grain products (serving/d) | 5.06 | 4.73 | 4.74 | 5.27 | 0.07 | 4.88 | 5.08 | 4.89 | 4.99 | 0.96 |
| Red and processed meats (serving/d) | 0.15 | 0.25 | 0.18 | 0.36 | 0.03 | 0.16 | 0.27 | 0.17 | 0.37 | 0.56 |
| Sweetened beverages (ml/d) | 0.01 | 0.12 | 0.02 | 0.18 | 0.005 | 0.02 | 0.14 | 0.02 | 0.17 | 0.87 |
| Salt (g/d) | 2499.61 | 1624.83 | 2451.50 | 2118.69 | 0.47 | 2463.82 | 1952.80 | 2484.36 | 1864.94 | 0.76 |
| DASH score | 27.88 | 2.93 | 27.44 | 3.24 | < 0.001 | 27.67 | 3.18 | 27.59 | 3.03 | 0.50 |
| Vegetables (g/d) | 311.82 | 183.88 | 297.39 | 200.62 | 0.03 | 298.35 | 186.79 | 310.64 | 201.22 | 0.07 |
| Non-refined cereals | 145.83 | 137.73 | 136.11 | 153.93 | 0.06 | 140.30 | 147.99 | 140.65 | 145.76 | 0.94 |
| Total cereal (g/d) | 305.25 | 143.43 | 308.81 | 160.81 | 0.51 | 309.07 | 155.79 | 304.93 | 150.12 | 0.44 |
| Fermented dairy (g/d) | 454.47 | 139.95 | 455.03 | 140.51 | 0.91 | 451.21 | 138.84 | 459.20 | 141.87 | 0.10 |
| Legume, nut and seed (g/d) | 41.78 | 57.26 | 43.10 | 77.73 | 0.59 | 43.05 | 67.73 | 41.84 | 71.28 | 0.62 |
| Total dairy (g/d) | 453.33 | 311.28 | 452.23 | 328.80 | 0.92 | 452.16 | 324.26 | 453.41 | 317.11 | 0.91 |
| Low fat dairy (g/d) | 84.02 | 151.02 | 87.02 | 163.49 | 0.59 | 83.13 | 154.52 | 88.84 | 162.27 | 0.30 |
| Red meat (g/d) | 15.28 | 16.61 | 18.77 | 26.32 | < 0.001 | 16.69 | 17.95 | 17.85 | 27.23 | 0.14 |
| Process meat (g/d) | 2.62 | 7.58 | 2.97 | 8.09 | 0.21 | 3.01 | 8.58 | 2.57 | 6.88 | 0.11 |
| Poultry (g/d) | 70.54 | 76.37 | 76.79 | 94.39 | 0.04 | 71.08 | 87.19 | 77.61 | 86.33 | 0.03 |
| Fish (g/d) | 2.16 | 21.41 | 3.53 | 32.81 | 0.17 | 3.11 | 29.43 | 2.68 | 26.83 | 0.66 |
| Total meat (g/d) | 87.67 | 79.42 | 96.02 | 101.69 | 0.01 | 89.08 | 91.20 | 96.27 | 93.94 | 0.02 |
| MUFA/SFA (g/d) | 0.89 | 0.30 | 0.89 | 0.33 | 0.70 | 0.91 | 0.33 | 0.88 | 0.29 | 0.005 |
| Fruits (g/d) | 288.48 | 213.12 | 304.81 | 222.66 | 0.03 | 299.77 | 222.16 | 294.72 | 214.08 | 0.51 |
| Oleic/SFA (g/d) | 0.69 | 0.23 | 0.69 | 0.23 | 0.65 | 0.71 | 0.24 | 0.67 | 0.22 | < 0.001 |
| Med diet score | 3.20 | 1.32 | 3.51 | 1.41 | < 0.001 | 3.44 | 1.41 | 3.29 | 1.33 | 0.002 |
NAFLD: nonalcoholic fatty liver disease; DASH: Dietary Approaches to Stop Hypertension, MeD: Mediterranean diet; MUFA: monounsaturated fatty acids; SFA: saturated fatty acid.
Significant at P < 0.05 for Independent t-test for continuous variables.
Multivariable-adjusted odds ratio and 95% confidence intervals for nonalcoholic fatty liver disease (NAFLD) according to tertiles of dietary patterns in all adult participants and stratified by sex, Amol Cohort Study, Iran, 2016–2017 (n 3220).
| DASH | MeD | |||||||
|---|---|---|---|---|---|---|---|---|
| Tertile 1 | Tertile 2 | Tertile 3 | Ptrend | Tertile 1 | Tertile 2 | Tertile 3 | Ptrend | |
| Median score | 25 | 28 | 31 | 2 | 4 | 5 | ||
| NAFLD cases (N, %) | 1386 (43) | 981 (30.5) | 853 (26.5) | 1675 (52) | 886 (27.5) | 659 (20.5) | ||
| Model 1 | Ref | 0.99 (CI 0.84–1.17) | 0.81 (CI 0.68–0.96) | 0.02 | Ref | 1.01 (CI 0.75–1.36) | 0.63 (CI 0.45–0.90) | 0.003 |
| Model 2 | Ref | 1.00 (CI 0.84–1.18) | 0.79 (CI 0.66–0.94) | 0.01 | Ref | 1.11 (CI 0.94–1.32) | 0.65 (CI 0.53–0.79) | 0.005 |
| Model 3 | Ref | 1.02 (CI 0.85–1.21) | 0.80 (CI 0.66–0.96) | 0.02 | Ref | 1.07 (CI 0.90–1.27) | 0.64 (CI 0.52–0.78) | 0.002 |
| Median score | 26 | 28 | 31 | 2 | 4 | 5 | ||
| NAFLD cases (N, %) | 570 (39.6) | 469 (32.6) | 399 (27.7) | 820 (57) | 392 (27.3) | 226 (15.7) | ||
| Model 1 | Ref | 0.95 (CI 0.74–1.23) | 0.73 (CI 0.56–0.95) | 0.02 | Ref | 1.15 (CI 0.90–1.48) | 0.65 (CI 0.33–0.65) | 0.006 |
| Model 2 | Ref | 1.02 (CI 0.76–1.36) | 0.71 (CI 0.52–0.97) | 0.04 | Ref | 1.13 (CI 0.85–1.50) | 0.43 (CI 0.30–0.63) | 0.006 |
| Model 3 | Ref | 1.02 (CI 0.76–1.36) | 0.72 (CI 0.53–0.98) | 0.05 | Ref | 1.10 (CI 0.83–1.47) | 0.42 (CI 0.29–0.61) | 0.004 |
| Median score | 25 | 29 | 31 | 2 | 4 | 5 | ||
| NAFLD cases (N, %) | 816 (45.8) | 512 (28.7) | 454 (25.5) | 855 (48) | 494 (27.7) | 433 (24.3) | ||
| Model 1 | Ref | 1.04 (CI 0.83–1.30) | 0.93 (CI 0.74–1.18) | 0.64 | Ref | 1.04 (CI 0.83–1.30) | 0.77 (CI 0.61–0.98) | 0.12 |
| Model 2 | Ref | 1.03 (CI 0.78–1.34) | 0.89 (CI 0.67–1.19) | 0.52 | Ref | 1.11 (CI 0.85–1.45) | 0.72 (CI 0.54–0.95) | 0.12 |
| Model 3 | Ref | 1.01 (CI 0.77–1.33) | 0.88 (CI 0.66–1.17) | 0.45 | Ref | 1.06 (CI 0.81–1.40) | 0.70 (CI 0.53–0.94) | 0.07 |
DASH: Dietary Approaches to Stop Hypertension, MeD: Mediterranean diet, Ref: reference category.
Model 1: adjusted for age and sex.
Model 2: Additional adjustment for BMI, energy intake, physical activity, and smoking.
Model 3: additional adjustment for Lowering serum lipid drugs, Lowering HPTN drugs, Lowering serum glucose drugs, residual areas, heart disease, diabetes.
Multivariable-adjusted odds ratio and 95% confidence intervals for nonalcoholic fatty liver disease (NAFLD) according to tertiles (T) of dietary patterns in all adult participants stratified by waist circumference, Amol Cohort Study, Iran, 2016–2017 (n = 3220).
| DASH | MeD | |||||||
|---|---|---|---|---|---|---|---|---|
| Tertile 1 | Tertile 2 | Tertile 3 | Ptrend | Tertile 1 | Tertile 2 | Tertile 3 | Ptrend | |
| NAFLD cases (N, %) | 134 (43.8) | 97 (31.7) | 75 (24.5) | 166 (54.2) | 88 (28.8) | 52 (17) | ||
| Model 1 | Ref | 1.07 (CI 0.80–1.45) | 0.89 (CI 0.65–1.23) | 0.57 | Ref | 1.01 (CI 0.75–1.36) | 0.63 (CI 0.45–0.90) | 0.05 |
| Model 2 | Ref | 1.05 (CI 0.78–1.43) | 0.85 (CI 0.61–1.18) | 0.39 | Ref | 0.98 (CI 0.72–1.33) | 0.64 (CI 0.45–0.92) | 0.05 |
| Model 3 | Ref | 1.03 (CI 0.76–1.40) | 0.87 (CI 0.63–1.21) | 0.40 | Ref | 0.96 (CI 0.71–1.31) | 0.64 (CI 0.45–0.91) | 0.04 |
| Abdominal obesitya cases | 497 (43.9) | 357 (31.6) | 277 (24.5) | 600 (53.1) | 343 (30.3) | 188 (16.6) | ||
| Model 1 | Ref | 0.95 (CI 0.75–1.21) | 0.76 (CI 0.59–0.96) | 0.03 | Ref | 1.16 (CI 0.92–1.46) | 0.65 (CI 0.50–0.84) | 0.05 |
| Model 2 | Ref | 0.98 (CI 0.77–1.25) | 0.76 (CI 0.59–0.98) | 0.04 | Ref | 1.21 (CI 0.95–1.55) | 0.64 (CI 0.49–0.83) | 0.07 |
| Model 3 | Ref | 0.97 (CI 0.76–1.24) | 0.75 (CI 0.57–0.97) | 0.04 | Ref | 1.17 (CI 0.92–1.50) | 0.62 (CI 0.47–0.81) | 0.03 |
DASH: dietary approaches to stop hypertension, MeD: Mediterranean diet, Ref: reference category.
Model 1: adjusted for age and sex.
Model 2: additional adjustment for BMI, energy intake, physical activity, and smoking.
Model 3: additional adjustment for Lowering serum lipid drugs, Lowering HPTN drugs, Lowering serum glucose drugs, residual areas, heart disease, diabetes.
aAbdominal obesity: waist circumference > 102 cm for men and > 88 cm for women.
Figure 1Flowchart of the study design.